会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 29. 发明申请
    • LED control circuit
    • LED控制电路
    • US20060033443A1
    • 2006-02-16
    • US11199710
    • 2005-08-09
    • Takaaki IshiiNobuyuki Ohtaka
    • Takaaki IshiiNobuyuki Ohtaka
    • H05B39/10
    • H05B33/0842H05B33/086H05B33/0863
    • An LED control circuit for controlling a plurality of LEDs with different emission colors comprises a counter which increments or decrements a count value at a predetermined clock in response to a count start signal externally supplied, a signal conversion circuit which converts the count value into an analog signal displaying intensity corresponding to the count value and outputs the analog signal as an output signal, a signal generation circuit which generates, based on the output signal from the signal conversion circuit and brightness data externally specified to its corresponding LED, an analog signal displaying intensity corresponding to a product of the output signal and the brightness data, and a driving circuit which drives its corresponding LED according to the analog signal output from the signal generation circuit, to gradually and simultaneously change the brightness of the LEDs in accordance with the count value.
    • 用于控制具有不同发光颜色的多个LED的LED控制电路包括响应于外部提供的计数开始信号而在预定时钟增加或减少计数值的计数器,将计数值转换为模拟信号的信号转换电路 信号显示强度对应于计数值,并输出模拟信号作为输出信号;信号产生电路,根据来自信号转换电路的输出信号和外部指定给其相应LED的亮度数据产生模拟信号显示强度 对应于输出信号和亮度数据的乘积的驱动电路,以及根据从信号发生电路输出的模拟信号驱动其对应的LED的驱动电路,根据计数值逐渐并且同时改变LED的亮度 。
    • 30. 发明授权
    • Remedial agent for anxiety neurosis or depression and piperazine derivative
    • 焦虑神经症或抑郁症和哌嗪衍生物的补救剂
    • US06949552B2
    • 2005-09-27
    • US10311429
    • 2001-06-27
    • Atsuro NakazatoShigeyuki ChakiTaketoshi OkuboShin-ichi OgawaTakaaki Ishii
    • Atsuro NakazatoShigeyuki ChakiTaketoshi OkuboShin-ichi OgawaTakaaki Ishii
    • A61K31/495A61K31/496A61K45/06A61P25/22A61P25/24C07D295/125C07D401/06C07D403/06C07D413/14
    • C07D295/125A61K31/495A61K31/496A61K45/06C07C2601/02C07C2601/08C07C2601/14
    • There are provided a therapeutic preparation for anxiety neurosis or depression which comprises a MC4 receptor antagonist as an effective ingredient; and a piperazine derivative represented by Formula [1]: [wherein Ar1 is a phenyl group, a substituted phenyl group, a naphthyl group or a substituted naphthyl group; Ar2 is a naphthyl group, a substituted naphthyl group, a quinolyl group, a group represented by the formula: (wherein R4 is a hydrogen atom or a halogen atom; and X—Y is CH—NH, CH—O, CH—S or N—O) or a group represented by the formula: (wherein R5 is a hydrogen atom, a hydroxyl group or a C1-10 alkoxy group); R1 is a hydrogen atom, a C1-10 alkyl group, a C3-8 cycloalkyl group, a C3-10 alkenyl group, a phenyl group, a 1-cyanoethyl group, a pyrimidin-2-yl group or an amidyl group; R2 and R3 are the same or different, and are each a hydrogen atom or a C1-10 alkyl group; A-B is N—CH2, CH—CH2, C(OH)—CH2 or C═CH; T1 is a single bond, —N(R6)— (wherein R6 is a hydrogen atom or a C1-10 alkyl group), —O—, —CH═CH— or —C(═O)—; n is an integer of from 1 to 10 and when T1 is a single bond, —CH═CH— or —C(═O)—, n is an integer of from 2 to 10 when T1 is —N(R6)— or —O—], or a pharmaceutically acceptable salt thereof.
    • 提供焦虑性神经症或抑郁症的治疗剂,其包含作为有效成分的MC 4受体拮抗剂; 和由式[1]表示的哌嗪衍生物:其中Ar 1是苯基,取代的苯基,萘基或取代的萘基; Ar 2是萘基,取代的萘基,喹啉基,由下式表示的基团:(其中R 4是氢原子或卤素原子; 并且XY是CH-NH,CH-O,CH-S或NO)或由下式表示的基团:(其中R 5是氢原子,羟基或C 1-10个烷氧基); R 1是氢原子,C 1-10烷基,C 3-8环烷基,C 3 -10个链烯基,苯基,1-氰基乙基,嘧啶-2-基或酰氨基; R 2和R 3相同或不同,并且各自为氢原子或C 1-10烷基; A-B是N-CH 2,CH-CH 2,C(OH)-CH 2或C-CH; T 1是单键,-N(R 6) - (其中R 6是氢原子或C 1 -10个烷基),-O - , - CH-CH-或-C( - O) - ; n是1〜10的整数,当T 1是单键时,-CH-CH-或-C(-O) - ,n是2〜10的整数,当T 或其药学上可接受的盐,其中R 1是-N(R 6) - 或-O-]。